WO2022175648A1 - Layered detection device - Google Patents
Layered detection device Download PDFInfo
- Publication number
- WO2022175648A1 WO2022175648A1 PCT/GB2022/050398 GB2022050398W WO2022175648A1 WO 2022175648 A1 WO2022175648 A1 WO 2022175648A1 GB 2022050398 W GB2022050398 W GB 2022050398W WO 2022175648 A1 WO2022175648 A1 WO 2022175648A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- detection
- layer
- transfer layer
- biological sample
- detection layer
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 502
- 239000010410 layer Substances 0.000 claims abstract description 527
- 238000012546 transfer Methods 0.000 claims abstract description 220
- 239000000090 biomarker Substances 0.000 claims abstract description 135
- 239000012472 biological sample Substances 0.000 claims abstract description 109
- 239000012790 adhesive layer Substances 0.000 claims abstract description 77
- 239000000853 adhesive Substances 0.000 claims abstract description 42
- 230000001070 adhesive effect Effects 0.000 claims abstract description 41
- 230000008859 change Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 10
- 239000012491 analyte Substances 0.000 description 39
- 206010052428 Wound Diseases 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 102000003896 Myeloperoxidases Human genes 0.000 description 16
- 108090000235 Myeloperoxidases Proteins 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000000463 material Substances 0.000 description 14
- 108010067372 Pancreatic elastase Proteins 0.000 description 11
- 102000016387 Pancreatic elastase Human genes 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- -1 for example cells Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 108010028275 Leukocyte Elastase Proteins 0.000 description 4
- 102000016799 Leukocyte elastase Human genes 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000013382 Gelatinases Human genes 0.000 description 2
- 108010026132 Gelatinases Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108090000899 Serralysin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 231100000749 chronicity Toxicity 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000009581 negative-pressure wound therapy Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000016761 Haem oxygenases Human genes 0.000 description 1
- 108050006318 Haem oxygenases Proteins 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007455 ileostomy Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011140 metalized polyester Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/525—Multi-layer analytical elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502707—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the manufacture of the container or its components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/525—Multi-layer analytical elements
- G01N33/526—Multi-layer analytical elements the element being adapted for a specific analyte
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/141—Preventing contamination, tampering
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5029—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures using swabs
Definitions
- the present invention relates to detection devices.
- layered detection devices for detection of one or more biomarkers in a biological sample/analyte.
- Biomarkers are naturally occurring molecules which can be used to identify biological processes, diseases, or medical conditions. As such, they are extremely useful in a wide range of applications such as in medicine. Accurate detection of biomarkers is therefore very important if biomarkers are to be used to diagnose a patient and provide treatment.
- biomarker detection devices have been developed that are integrated within a medical device, such as a wound dressing, to provide near-immediate detection of a particular biomarker. These devices typically work by recognising the biomarker through a bio-chemical reaction within a detection region of the device. Successful detection can then be assessed by a change in the device caused by the reaction, for example a visual change.
- WO2017/173069 discloses a device comprising a reaction layer adhered to a bottom layer by an adhesive layer. The adhesive layer is the same shape as the reaction layer to ensure exact fixation.
- the reactions used to detect a biomarker are complex bio-chemical processes that are very sensitive to their environment.
- teh visual change in the device caused by the reaction can also be a complex process that is strongly dependent on the local environment. Where the environment is not optimised for the detection and visualisation processes this can lead to inaccurate biomarker detection and/or interpretation of the detection result.
- a detection device may need to be small so that it may fit within a swab tube, medical device tubing, or wound dressing.
- the reduced physical size of the device can make it hard to observe any changes in the device that indicate the detection of a biomarker.
- biomarker detection in which the detection reactions are provided in an environment that is more conducive to accurate detection of a biomarker and visualisation of the detection result, ideally while maintaining a small form factor suitable for integration into other medical devices.
- a detection device comprising: a detection layer configured to detect one or more markers in a biological sample or analyte; and a transfer layer in direct contact with a first surface of the detection layer, wherein the transfer layer is configured to deliver the biological sample or analyte directly to the detection layer.
- the biological sample may be an analyte; the terms biological sample and analyte may be used interchangeably herein.
- a biological sample may be defined as a biological material acquired or derived from living or deceased beings, including but not limited to the following: human (or animal) tissue — fresh, frozen, fixed or processed (e.g., sectioned); all human (or animal) blood (e.g., peripheral or umbilical cord) and blood by-products (e.g., serum, plasma, huffy coat); all human (or animal) biofluids (e.g., sputum, urine, bile); human (or animal) primary cells derived from a human (or animal) body; DNA derived from individual donors.
- a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in an analyte; and a transfer layer in direct contact with a first surface of the detection layer, wherein the transfer layer is configured to deliver the analyte directly to the detection layer and an observation window is provided on a second surface of the detection layer opposite the transfer layer.
- a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample; and a transfer layer in direct contact with a first surface of the detection layer, wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and an observation window is provided on a second surface of the detection layer opposite the transfer layer.
- the transfer layer is configured to deliver a biological sample directly to the detection layer, i.e., not through an intervening adhesive layer.
- the transfer layer preferably there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window.
- the observation window is free of adhesive.
- a biomarker is delivered to the detection layer without passing through an intermediate adhesive layer that may obstruct passage of the biological sample.
- the absence of additional layers between eh transfer layer and the detection layer also avoids introduction of additional chemicals or substances to the detection layer, which could obstruct or interfere with the operation of the detection layer (e.g., interfering with a colour change that occurs on detection). This improves the performance of the detection layer as the reaction environment is better optimised for detecting the one or more biomarkers, and also ensures the resultant change in the detection layer is more predictable and consistent.
- the device can be constructed of only a few layers of material and does not require a dedicated fluid connection component between the transfer and detection layers, it is also of low complexity and can be easily manufactured and integrated into medical devices such as wound dressings, or swab receptables. This allows for in-situ detection of biomarkers in a wide range of applications.
- the transfer layer and detection layer may be bonded together at a location that is out of register with the observation window.
- the transfer layer and detection layer are not bonded together at all where they are in register with the observation window - this ensures the bonding does not interfere with the region where the detection result will be seen.
- the transfer layer and the detection layer are not bonded together at least in the majority of the region where they are in register with the observation window, or, in increasing preferability they are not bonded together in at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the region in register with the observation window.
- a bonding force between the transfer layer and detection layer may be provided out of register with the observation window. Less than 30%, 20%, 10%, 5%, 1%, or 0.5% of the total bonding force provided between the transfer layer and detection layer may be provided in the region in register with the observation window. Thus, the detection layer and transfer layer are bonded together at locations outside the observation window ensuring the bonding mechanism does not affect biomarker detection.
- the transfer layer may comprise a first surface and a second surface on opposite sides of the transfer layer.
- the first surface of the transfer layer may be configured to receive the biological sample into the transfer layer.
- the second surface of the transfer layer may be configured to deliver the biological sample to the detection layer.
- the detection layer may comprise a first surface and a second surface on opposite sides of the detection layer.
- the first surface of the detection layer may be configured to receive the biological sample into the detection layer from the transfer layer.
- the second surface of the detection layer may be an observation surface configured to allow changes in the detection layer to be observed. At least part of the second surface of the transfer layer may be in direct contact with the first surface of the detection layer.
- the biological sample and one or more biomarkers may pass directly from the transfer layer to the detection layer in unbonded regions without being impeded by the bonding mechanism.
- the second surface of the detection layer may be bonded to the transfer layer. Only part of the second surface of the detection layer may be bonded to part of the second surface of the transfer layer.
- the second surfaces of the transfer and detection layers may not be in direct contact. Thus, with the detection layer and transfer layer bonded together by their second surfaces, the bond does not affect the first surface of the detection layer through with the biomarker is introduced to the detection layer.
- the device may comprise an adhesive layer provided on only part of the second surface of the detection layer.
- the observation window may comprise an opening in the adhesive layer.
- the adhesive layer may bond to the detection layer and the transfer layer.
- the adhesive layer may bond the second surface of the detection layer to part of the second surface of the transfer layer.
- the transfer layer may extend beyond at least one edge of the detection layer.
- the adhesive layer may bond to the transfer layer beyond at least one edge of the detection layer.
- the adhesive layer bonds the transfer and detection layers together by their respective second surfaces, this reduces the possibility of adhesive interacting with the biological sample because the biological sample does not pass through the adhesive when entering the detection layer.
- the invention contemplates heat bonding, stitch bonding, or mechanically clamping the transfer layer to the detection layer, for example around their outer edges.
- the device may further comprise a label.
- the label may be bonded to the second surface of the detection layer.
- the label may be a layer.
- the label may be bonded to the detection layer by the adhesive layer.
- the observation window may comprise an opening in the label (and the adhesive layer if present).
- a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample; and a transfer layer in direct contact with a first surface of the detection layer; wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and wherein an observation window is provided on a second surface of the detection layer opposite the transfer layer and wherein there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window, wherein the transfer layer comprises a first surface configured to receive the biological sample into the transfer layer and a second surface configured to deliver the biological sample to the detection layer, and the first surface of the detection layer is configured to receive the biological sample into the detection layer from the transfer layer, wherein at least part of the second surface of the transfer layer is in direct contact with the first surface of the detection layer, wherein only part of the second surface of the transfer layer is bonded to only part of the second surface of the detection layer, wherein the device further comprises an adhesive layer provided on only part of the second surface of the detection layer, wherein the observation window
- a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample; and a transfer layer in direct contact with a first surface of the detection layer; wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and wherein an observation window is provided on a second surface of the detection layer opposite the transfer layer and wherein there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window, wherein the transfer layer comprises a first surface configured to receive the biological sample into the transfer layer and a second surface configured to deliver the biological sample to the detection layer, and the first surface of the detection layer is configured to receive the biological sample into the detection layer from the transfer layer, wherein at least part of the second surface of the transfer layer is in direct contact with the first surface of the detection layer, wherein only part of the second surface of the
- the label may be stiffer and/or stronger than the adhesive layer, and/or than the detection layer, and/or than the transfer layers.
- a label can be provided on the device which reduces the risk of misinterpretation of the result.
- the label may also provide structural support to the device if necessary.
- the provision of a label layer can provide additional structural stability to the adhesive layer that bonds the second surface of the detection layer to the second surface of the transfer layer.
- the detection layer may be configured to change colour in response to the presence of the one or more biomarkers.
- the colour change may be chromogenic.
- the marking may include the possible colours that the detection layer may display in response to the presence of the one or more predetermined biomarkers.
- the device provides simple visual interpretation of the detection result.
- the marking may additionally or alternatively indicate which one or more predetermined biomarker the detection layer detects.
- the device may further comprise a fixing element.
- the fixing element may be provided at an outer surface of the device, for example, the label.
- the fixing element may be configured to attach or adhere the device to another object, such as part of a medical device.
- a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample; and a transfer layer in direct contact with a first surface of the detection layer; wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and wherein an observation window is provided on a second surface of the detection layer opposite the transfer layer and wherein there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window, wherein the transfer layer comprises a first surface configured to receive the biological sample into the transfer layer and a second surface configured to deliver the biological sample to the detection layer, and the first surface of the detection layer is configured to receive the biological sample into the detection layer from the transfer layer, wherein at least part of the second surface of the transfer layer is in direct contact with the first surface of the
- the fixing element may be an adhesive layer on a surface of the label opposite the detection layer.
- the fixing element may comprise an adhesive, or any other suitable surface that can provide fixation, such as one element of a hook and loop, or hook and hook seal, or a magnetic surface to be attracted to a corresponding magnetic surface on another device.
- the fixing element may be shaped to correspond with a fitting element so that the detection device may be attached to an object containing the fitting element. For example, through a push-fit, bayonet, or screw fitting, or similar.
- the fixing element may comprise a removeable liner, such as a release layer.
- a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample; and a transfer layer in direct contact with a first surface of the detection layer; wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and wherein an observation window is provided on a second surface of the detection layer opposite the transfer layer and wherein there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window, wherein the transfer layer comprises a first surface configured to receive the biological sample into the transfer layer and a second surface configured to deliver the biological sample to the detection layer, and the first surface of the detection layer is configured to receive the biological sample into the detection layer from the transfer layer, wherein at least part of the second surface of the transfer layer is in direct contact with the first surface of the detection layer, wherein only part of the second surface of the transfer layer is bonded to only part of the second surface of the detection layer, wherein the device further comprises an adhesive layer provided on only part of the second surface of the detection layer, wherein the observation window
- the liner may prevent the device being fixed to an object until the liner is removed, and prevent access to the observation window until the liner is removed.
- the device can be conveniently fixed to other objects such as medical devices to provide in-situ biomarker detection, the releasable liner further prevents tampering or interference with the device by protecting the observation window until use.
- the observation window may comprise openings in any one or more of the adhesive layer, label, and fixing element.
- the fixing element comprises a releasable liner
- the releasable liner may be configured to cover the openings.
- Each opening may be in substantially the same position.
- Each opening may be substantially the same shape and size.
- the openings may be of different shapes or sizes, provided they are sufficiently aligned that there is a clear “line of sight” un-obscured by any of the adhesive layer, label or fixing element.
- the observation of the detection layer through the observation window is not obscured or altered by any of the adhesive layer, label, or fixing element.
- the observation window thus ensures that the section of the detection layer in which a change may be observed does not itself comprise additional unnecessary material that could change the detection layer’s appearance. Furthermore, the observation window allows for direct assessment of the change in the detection layer without additional unnecessary material potentially obscuring the layer and causing misinterpretation of the result.
- the device comprises an adhesive layer, label, and fixing element, wherein the fixing element is an outer adhesive layer applied to a surface of the label opposite the detection layer, and the observation window comprises openings in the adhesive layer, label and, outer adhesive layer, and wherein the openings are all in substantially the same position and are preferably substantially the same shape and size.
- the device and/or layers of the device may be any suitable shape, for example an irregular polygon or regular polygon, such as a square, a rectangle, a circle, or an ellipse.
- the device and/or layers of the device may be an arbitrary 2D shape.
- the shape of the device and/or layers of the device may coincide with branding or a brand logo, or may coincide with the shape of a medical device in which the detection device is intended to be integrated.
- the transfer layer and/or detection layer and/or observation window may be the same shape, or may be different shapes.
- the device and/or layers of the device may be any suitable size.
- the transfer layer may define the size and/or shape of the device.
- the transfer layer may be larger than the detection layer.
- the detection layer may be larger than the observation window.
- the transfer layer may have an area at least 2, 3, 4, 5, or 6 times the area of the detection layer.
- the detection layer may have an area of at least 10 mm 2 , 20 mm 2 , 30 mm 2 , 50 mm 2 , or 100 mm 2 .
- the detection layer may have an area less than 100 mm 2 , 50 mm 2 , 30 mm 2 , or 20 mm 2 .
- the observation window may have an area of at least 2 mm 2 , 6 mm 2 , 10 mm 2 , 20 mm 2 , or 50 mm 2 .
- the observation window may have an area less than 50 mm 2 , 20 mm 2 , 10 mm 2 , or 6 mm 2 .
- the label and the transfer layer may be the same size
- the detection layer may comprise at least two detection zones, for example three or more detection zones.
- the detection zones may be laterally adjacent to one another.
- the detection zones may be arranged in any suitable shape, for example along a line or along the circumference of a circle.
- Each detection zone may be configured to detect a different set of one or more biomarkers.
- One or more of the detection zones may be configured to detect the presence of the biological sample, that is one or more detection zones may be a control zone, thus providing a check to show the biological sample has successfully penetrated the detection layer.
- One or more detection zones may be configured to (separately) detect the presence of the biological sample and whether the biological sample comprises one or more biomarkers.
- a single zone may detect both the presence of a biological sample and whether it comprises one or more biomarkers.
- a single detection zone may change from a first colour to a second colour in the presence of a biological sample not containing one or more biomarkers and from the first colour to a third colour in the presence of one or more biomarkers.
- the single zone may comprise a pH responsive composition and change from the first colour to the second in the presence of a biological sample in a “normal” state and from the first colour to the third colour in the presence of a biological sample having a biomarker (i.e. elevated or reduced pH) associated with an infected wound.
- the device may comprise at least two observation windows, for example three or more observation windows. Each observation window may correspond to a respective detection zone.
- the detection layer comprises three detection zones, and three observation windows, wherein each observation window corresponds to a respective detection zone.
- the detection zones are preferably positioned laterally relative to one another in a line.
- the device can be arranged to detect multiple different sets of biomarkers simultaneously allowing for complex detection of one or more medical conditions or diseases.
- Each detection zone may be provided by an independent detection segment.
- the independent detection segments may thus, together form the detection layer.
- Each independent detection segment may be independently bonded to (and in direct contact with) the transfer layer.
- the detection segments may be adjacent (to provide a small form-factor) or spaced from one another (to avoid unintended interaction between the compositions in the segments).
- the spacing between adjacent detection segments may be at least 0.5 mm, 1.0 mm, 1.5 mm, 2.0 mm, 4.0 mm, or 10 mm.
- the spacing between adjacent detection segments may be less than 10 mm, 4.0 mm, 2.0 mm, 1.5 mm, or 1.0 mm.
- Each detection segment may have an area of at least 10 mm 2 , 20 mm 2 , 30 mm 2 , 50 mm 2 , or 100 mm 2 .
- Each detection segment may have an area less than 100 mm 2 , 50 mm 2 , 30 mm 2 , or 20 mm 2 .
- the transfer layer may be configured to distribute the biological sample to each detection zone. Thus, the transfer layer ensures each detection zone is supplied with a sufficient amount of the biological sample.
- the transfer layer may be bonded to the detection layer between adjacent detection zones.
- One or more gaps may be provided between adjacent observation windows. Each gap may be at least 1, 2, 3, 4 or 5 times the width of each observation window as measured in the same direction as the gap. Each gap may be at least 0.5 mm, 1.0 mm, 1.5 mm, 2.0 mm, 5 mm, 10 mm or 20 mm. Each gap may be less than 30 mm, 20 mm, 10 mm, 5 mm, 2.5 mm, 1.5 mm, or 1.0 mm. Each gap may be the same size or may vary in size depending on the device construction and detection zone configuration.
- the transfer layer may be bonded to the detection layer in the one or more gaps.
- the transfer layer and detection layer are bonded between adjacent detection zones to ensure direct contact between the transfer layer and detection layer is provided in each detection zone.
- the bonding is only present in the gaps between each observation window ensuring the bonding does not affect the detection results.
- the detection layer may be formed from one or more biomarker detection strips, for example the detection segments may be cut from a biomarker detection strip. Each detection zone may be provided by a respective biomarker detection strip.
- the biomarkers detected by embodiments of the present invention may represent any indicator of a normal biological process, pathogenic process, or pharmacological response.
- One or more of the biomarkers may be a biomarker known to be present in an infected or chronic wound, or related to any of the following: neutrophil activity; macrophage activity; white blood cell activity; innate immune system activity, such as patient neutrophil/macrophage/white blood cell enzyme activity, protease activity, peroxidase activity, and pH/acidity/alkalinity; microbial activity, such as bacterial, fungal or biofilm activity; pathogen activity, such as microbial/bacterial/fungal/pathogen presence, contamination or colonisation; inflammation, such as bacteria-r elated, pathogen-related or biofilm related inflammation; chronicity, such as bacteria-r elated, pathogen-related or biofilm-related chronicity; infection, such as local or spreading infections; and, sepsis.
- suitable biomarkers include: proteins, such as granulocyte-macrophage colony- stimulating factor, fibrin; enzymes, such as myeloperoxidase, neutrophil elastase, lysozyme, cathepsin G, elastase, lipase, esterase, catalase, Proteinase 3, gelatinase, collagenase, matrix metalloproteinases, stromolysins, matrilysins, alkinaine, lipocalins, phosphatase superoxide dismutase, NAPPH oxidase, haem oxygenase; cytokines; interleukins; antibodies; cells (prokaryotic or eukaryotic); viruses; microbial enzymes such as ZapA/serralysin (from Proteus mirabilis); LasB/protease, Proteinase K, Lip A/lipase, LasA/protease or Para/serralysin
- a detection zone may be a control zone configured to detect the presence of the biological sample.
- the control zone may be configured to detect the pH of the biological sample and thus any colour change of the control zone indicates the biological sample’s presence in the detection layer.
- the user is presented with a simple visual check that shows if the device is functioning.
- the detection device is configured to detect three different biomarkers: myeloperoxidase, neutrophil elastase and pH.
- Each biomarker may be detected by an independent biomarker detection segment.
- the pH detection segment can be both a control zone, and also indicate if a specific pH level is present in the biological sample, for example a pH level indicative of an infection.
- the detection layer may be configured to detect one or more biomarkers using one or more reagents.
- the detection layer may be configured to detect the one or more biomarkers by combining the one or more reagents with the one or more biomarkers in the detection layer.
- the detection layer may be configured to detect the one or more biomarkers through a reaction between the one or biomarkers and the one or more reagents (in the detection layer).
- a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample; and a transfer layer in direct contact with a first surface of the detection layer; wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and wherein an observation window is provided on a second surface of the detection layer opposite the transfer layer and wherein there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window, wherein the transfer layer is configured to release one or more reagents into the biological sample, and wherein the detection layer is configured to detect the one or more biomarkers by combining the one or more reagents with the one or more biomarkers in the detection layer.
- the reagent may comprise an enzyme- reactive indicator.
- the transfer layer may be configured to release one or more reagents into the biological sample.
- the detection layer may be configured to release one or more reagents into the biological sample.
- the reagents may comprise any one or more: reactants; co-factors; catalysts; chemical substrates; biochemical substrates; and the like.
- the reagents may be glucose and glucose oxidase.
- the transfer layer may be configured to release glucose into the biological sample.
- the detection layer may be configured to release glucose oxidase into the biological sample.
- the biomarker may be myeloperoxidase.
- the detection layer may comprise one or more probes. Each probe may be configured to generate a signal when acted on by one or more biomarkers. Where the biomarker is an enzyme, the probe may comprise a modified enzyme substrate specific to the enzyme. Suitable biomarkers and their detectors and co-reagents are disclosed in WO2017/173069, the content of which is incorporated herein by reference.
- the detection layer may be configured to detect the one or more biomarkers using the one or more reagents.
- the detection layer may be configured to combine the one or more reagents with the one or more biomarkers in one or more of the detection zones.
- a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample and comprising two or more detection zones; and a transfer layer in direct contact with a first surface of the detection layer; wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and wherein an observation window is provided on a second surface of the detection layer opposite the transfer layer and wherein there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window, wherein the transfer layer is configured to release one or more reagents into the biological sample, and wherein the detection layer is configured to detect the one or more biomarkers using the one or more reagents.
- the transfer layer can distribute the sample/analyte and reagents among all detection zones where they can be used to assist detection of the one or more biomarkers in the detection layer/zone.
- the transfer layer may be configured to filter the biological sample.
- the transfer layer may be configured to inhibit parts of the biological sample from migrating to the detection layer.
- the transfer layer may be configured to thus remove and/or bind parts of the biological sample not required by the detection layer, for example cells, pigments, haemoglobin, debris or the like that could interfere with observation.
- the transfer layer may be configured to reduce colour changes in the detection layer that result from parts of the biological sample other than the one or more biomarkers.
- the transfer layer and detection layer work together to ensure accurate detection of the biomarkers, for example by preventing colour changes in the detection layer due to other constituents of the biological sample.
- the detection layer may change colour in response to the presence of a predetermined biomarker.
- the transfer layer may comprise colour- masking components to enhance the visibility of the colour change of the detection layer or to ensure any colour changes are primarily due to the detection of the one or more biomarkers by the detection layer (and not due to other components of the biological sample) as described above.
- the transfer layer and detection layer are preferably formed from filter paper. However in some embodiments, either may be formed from any one of the following: paper, mesh, membrane, film, polymer, polysulfone, resorbable film, bioresorbable film, nitrocellulose, or the like.
- the transfer layer and detection layer may be formed of the same material, or of different materials.
- the label may be formed of any of: paper, mesh, film, polymer, plastics, or the like.
- the transfer layer, and/or detection layer, and/or label may be at least 0.05 mm, 0.1 mm, 0.5 mm, 1 mm, 2 mm, 3 mm, 4 mm, 5 mm thick.
- the transfer layer, and/or detection layer, and/or label may be less than 10 mm, 8 mm, 6 mm, 4 mm, 2 mm, 1 mm thick. In one example, the transfer layer and detection layers are both 3 mm thick. In another example, the transfer layer is 0.16 mm thick. In one example, the detection layer is between 0.16 mm and 0.18 mm thick.
- the adhesive layer is preferably an acrylic-based laminate adhesive; however, many other types of adhesive would also be suitable.
- the adhesive layer could be any acrylate adhesive, or any fibre-reinforced transfer adhesive.
- the adhesive layer may be at least 10 pm, 25 pm, 50 pm, 100 pm, 200 pm, 400 pm, 1 mm, 2 mm, or 5 mm thick.
- the adhesive layer may be less than 5 mm, 2 mm, 1 mm, 400 pm, 200 pm, 100 pm, 50 pm, or 25 pm thick. In one example, the adhesive layer is 60 pm thick.
- the label is preferably a plastics material, however, many other types of material could be used, for example paper or card.
- the label is comprised of polypropylene (PP) and polyethylene terephthalate (PET).
- PP polypropylene
- PET polyethylene terephthalate
- Other plastics materials that the label may comprise include, for example: low density polyethylene (LDPE), metalized polyester (MET PET) or orientated polypropylene (OPP).
- a medical device comprising the biomarker detection device of the first aspect of the invention or the second aspect of the present invention, optionally including any of the optional features set out above.
- a medical device comprising a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample; and a transfer layer in direct contact with a first surface of the detection layer; wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and wherein an observation window is provided on a second surface of the detection layer opposite the transfer layer and wherein there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window.
- the medical device may be a swab receptacle; swab transport tube; or swab device. Accordingly, there is provided a swab receptacle comprising a biomarker detection device comprising: a detection layer configured to detect one or more biomarkers in a biological sample; and a transfer layer in direct contact with a first surface of the detection layer; wherein the transfer layer is configured to deliver the biological sample directly to the detection layer and wherein an observation window is provided on a second surface of the detection layer opposite the transfer layer and wherein there is no adhesive between the transfer layer and the detection layer in the region in register with the observation window.
- the medical device may be a wound dressing, such as a chronic wound dressing or a surgical/acute wound dressing.
- the medical device may be a tube, for example a catheter, such as an intermittent or indwelling urinary catheter, an airway catheter, a faecal catheter, or a central venous catheter.
- the medical device may be negative pressure wound therapy (NWPT) tubing, connectors, pumps and dressings.
- NWPT negative pressure wound therapy
- the medical device may be a wound drain tube, or a surgical drain tube.
- the medical device may be a wound drain bag, or a surgical drain bag.
- the medical device may be a NWPT reservoir or other wound drainage device.
- the medical device may be a debridement device (physical, physio- chemical, powered, or ultrasonic).
- the medical device may be a cannula, securement device or infusion device (e.g. insulin infusion device).
- the medical device may be a monitor/monitoring device, such as a glucose monitor.
- the medical device may be an airway management system.
- the medical device may a lung flow meter, or a breath flow meter.
- the medical device may be a face mask.
- the medical device may be an endotracheal tube, tracheostomy tube, an open suction system airway catheter, or a closed suction system airway catheter.
- the medial device may be an ostomy appliance or pouch, for example a colostomy, ileostomy, or urostomy appliance.
- the detection device can therefore be used in a wide variety of applications.
- a method of forming a (biomarker) detection device comprising: providing a detection layer configured to detect one or more (bio)markers in a biological sample; providing a transfer layer in direct contact with a first surface of the detection layer (not via an intervening adhesive layer); providing an observation window on a second surface of the detection layer opposite the transfer layer; and bonding the detection layer and transfer layer together (with the observation window being free from adhesive).
- the detection device may be a detection device according to any of the first to third aspects of the invention, optionally including any optional features set out above.
- a method of detecting one or more (bio)markers in a biological sample comprising: releasing the biological sample into a transfer layer; delivering the biological sample into a detection layer configured to detect the one or more (bio)markers; and, observing the detection of the one or more biomarkers in the detection layer through an observation window, wherein: the transfer layer is in direct contact with a first surface of the detection layer; and the observation window is provided on a second surface of the detection layer opposite the transfer layer.
- the detection device may be a detection device according to any of the first to third aspects of the invention, optionally including any optional features set out above.
- the invention also extends to a method of diagnosis based on detection of one or more (bio)markers in a biological sample, the method comprising: releasing the biological sample into a transfer layer; delivering the biological sample into a detection layer configured to detect the one or more (bio)markers; and, observing the detection of the one or more biomarkers in the detection layer through an observation window, wherein: the transfer layer is in direct contact with a first surface of the detection layer; and the observation window is provided on a second surface of the detection layer opposite the transfer layer; the method further comprising identifying a disorder responsible for the observed detection of one or more biomarkers.
- the detection device may be a detection device according to any of the first to third aspects of the invention, optionally including any optional features set out above.
- the invention may extend as far as prescribing a treatment in response to the observed detection of one or more biomarkers.
- Figure 1 is a cross-sectional view of a first embodiment of a detection device
- Figure 2 is a cross-sectional view of a second embodiment of a detection device
- Figure 3 is a top plan view of the detection device of Figure 2;
- Figure 4 is a cross-sectional view of a third embodiment of a detection device
- Figure 5 is a cross-sectional view of the detection device of Figure 4.
- Figure 6 is a cross-sectional view of the detection device of Figure 4 in use in a medical device
- Figure 7 is a top plan view of a fourth embodiment of a detection device
- Figure 8 is a cross-sectional view of the detection device of Figure 7.
- a first embodiment of a detection device 100 comprises a transfer layer 101, detection layer 102 and an adhesive layer 103 (from bottom to top in that order, as shown in the drawings).
- the transfer layer 101 comprises a first surface 101a (lowermost in the drawings) and a second surface 101b (uppermost in the drawings) on opposite sides of the transfer layer 101.
- the detection layer 102 also comprises a first surface 102a (lowermost in the drawings) and a second surface 102b (uppermost in the drawings) on opposite sides of the detection layer 102.
- the detection layer 102 is arranged on the transfer layer 101 such that the second surface 101b of the transfer layer 101 is in direct contact with the first surface 102a of the detection layer 102.
- the transfer layer 101 extends beyond two opposite lateral edges of the detection layer 102.
- the adhesive layer 103 is applied over the upper surfaces of the transfer layer 101 and the detection layer 102 and as such is arranged to bond to both: the second (upper) surface 102b of the detection layer 102; and the second (upper) surface 101b of the transfer layer 101 where it extends beyond the edges of the detection layer 102.
- the adhesive layer 103 thereby fixes the transfer layer 101 and detection layer 102 together so that the detection layer 102 is effectively clamped between the transfer layer 101 and the adhesive layer 103. This maintains direct contact between the transfer layer 101 and detection layer 102 without requiring adhesive to be present between them.
- the second surface 102b of the detection layer 102 includes an observation window 104.
- the observation window 104 comprises an opening in the adhesive layer 103 thereby providing an observation surface free from adhesive on the second surface 102b of the detection layer 102, where the upper surface of the detection layer can be viewed.
- the first surface 101a of the transfer layer 101 is configured to receive a biological sample which in this embodiment is referred to as an analyte (not shown) for example from a swab (not shown) into the transfer layer 101, and the second surface 101b of the transfer layer 101 is configured to deliver the analyte (which transfers through the transfer layer 101) to the detection layer 102.
- analyte for example from a swab (not shown) into the transfer layer 101
- the second surface 101b of the transfer layer 101 is configured to deliver the analyte (which transfers through the transfer layer 101) to the detection layer 102.
- the first surface 102a of the detection layer is configured to receive the analyte into the detection layer 102 from the transfer layer 101.
- the detection layer 102 is configured to detect one or more biomarkers (not shown) in the analyte by undergoing a change in response to the one or more biomarkers.
- the detection layer 102 undergoes a qualitative or quantitative colour (chromogenic) change in response to the presence of a predetermined biomarker.
- the observation window 104 is configured to allow a user to visualise the change in the detection layer 102.
- the detection device 100 is a biomarker detection device, but it is conceived that in other embodiments the device 100 may be configured to detect any suitable marker.
- the construction of the device 100 allows the transfer layer 101 to be configured to deliver the analyte directly to the detection layer 102, i.e. not through an intervening layer that may obstruct the analyte, such as an intervening adhesive layer. This improves detection performance in the device 100.
- the observation window 104 is free of adhesive and so the resultant change in the detection layer 102 is clearer.
- the transfer layer 101 is also configured to filter the contents of the analyte and provide reagents to the analyte to assist or enable the biomarker detection process in the detection layer 102. Further information on the biomarker detection process including examples of biomarkers and reagents is disclosed in WO2017/173069, the content of which is incorporated herein by reference.
- the transfer layer 101 and detection layer 102 are comprised of filter paper.
- the detection layer 102 also comprises biomarker-sensing chromogenic compositions that facilitates detection of the one or more biomarkers.
- each layer may comprise a different material, and a variety of materials would be suitable for each layer. For example, paper, mesh, film, polymer, resorbable film, bioresorbable film, or nitrocellulose.
- the adhesive layer 103 is provided by an acrylic adhesive.
- any suitable adhesive may be used, for example any acrylate adhesive, or any fibre-reinforced transfer adhesive.
- the device 100 can be constructed by cutting glucose filter paper which will form the transfer layer to a suitable size (as an example 1cm x 1cm square); cutting a detection strip of e.g. 5 mm width to form a 1 cm x 5 mm rectangle aligning the detection layer 102 centrally across the transfer layer 101 and applying an adhesive, for example a hot-melt adhesive, to the aligned transfer layer 101 and detection layer 102, such that the adhesive forms two strips at the edges along the transfer layer 101 perpendicular to the length of the detection layer 102, so as to attach its upper surface 102b to the upper surface 101b of the transfer layer 101, whilst leaving the central region free from adhesive to form the observation window.
- a suitable size as an example 1cm x 1cm square
- an adhesive for example a hot-melt adhesive
- the detection device 200 is a labelled device 200 and comprises a label 205 bonded to the adhesive layer 203 opposite the detection layer 202 (above it as shown in the drawings).
- the observation window 204 comprises opening in the label 205 and the adhesive layer 203.
- the respective openings are in the same position and as such ensure the detection layer 202 is not obscured by any unnecessary material.
- the label 205 further comprises two markings 211, 212.
- the markings 211, 212 are printed markings to aid interpretation of biomarker detection by the detection layer 202.
- the markings 211, 212 may be coloured to correspond to the colour of the detection layer 202 when a predetermined biomarker is present and/or may identify the predetermined biomarker that causes a colour- change in the detection layer.
- the label 205 is stiff.
- the label 205 provides additional structural stability to the adhesive layer 203 that bonds the detection layer 202 to the transfer layer 201, allowing a more flexible or breakable adhesive to be used.
- the label 205 comprises polypropylene (PP) and polyethylene terephthalate (PET), in other embodiments different materials may be used such as other plastics, paper, card or metal.
- the first step is cutting glucose filter paper which will form the transfer layer 201 to a suitable size (as an example 1cm x 1 cm square).
- a detection strip is cut to a suitable size, for example a 5 mm wide strip can be cut to a 10 mm x 5 mm rectangular detection segment, the detection segment is aligned to form the detection layer 202 extending centrally across the transfer layer 101.
- the label 205 can be cut from a larger laminate including the adhesive and a release liner. It is cut to match the size of the transfer layer 102, with an aperture formed centrally (e.g. using a suitably shaped hole punch) which is smaller than the width of the detection segment forming the detection layer 202, e.g. a 4 mm x 4 mm square.
- the release layer is removed and the label 205 adhered by the adhesive layer 203 to the upper surfaces of the detection layer 202 and the transfer layer 201, to clamp one to the other whilst leaving the central region free from adhesive or label to form the observation window 204.
- the detection device 300 is a self-adhesive device 300 and further comprises a fixing element on a surface of the label 305 opposite the detection layer 302.
- the fixing element comprises an outer adhesive layer 306 bonded to the label 305, and a releasable liner 307 on the outer surface of the outer adhesive layer 306.
- the outer adhesive layer 306 comprises an opening which forms part of the observation window 304, and is thus in the same position as the opening in the label 305 and adhesive layer 303.
- the releasable liner 307 does not comprise a corresponding opening, and as such spans the opening in the outer adhesive layer 306.
- the releasable liner 307 is thereby configured to prevent access to the detection layer 302 and also prevent the outer adhesive layer 306 from bonding to an object until the device 300 is ready to be used. This ensures the detection layer 302 is not interfered with by foreign objects or dirt, and also that the outer adhesive layer 306 can provide a strong and dependable bond between the device 300 and another object.
- the fixation provided by the fixing element is due to the outer adhesive layer 306 which is provided by an acrylic laminate.
- the fixing element may any other suitable surface that can provide fixation, such as other types of adhesive, one element of a hook and loop or hook and hook seal, or a magnetic surface to be attracted to a corresponding magnetic surface on another device.
- the fixing element may further be shaped to correspond with a fitting element so that the detection device may be attached to an object containing the fitting element. For example, through a push-fit, bayonet, or screw fitting, or similar.
- the device 300 is provided with the releasable liner 307 attached to the outer adhesive layer 306 (see Figure 5).
- the releasable liner 307 is removed exposing the adhesive surface of the outer adhesive layer 306 and the observation window 304 ( Figure 4).
- the device 300 can then be placed in a medical device where the analyte is received into the transfer layer 301 and biomarkers in the analyte are detected by the detection layer 302.
- the transfer layer 301, detection layer 302, adhesive layer 303, and label 305 can be built up exactly as described in respect of the second embodiment.
- An acrylic laminate adhesive with two release layers can then be cut to shape to match the external dimensions and aperture position, shape and size, then the lower release layer removed and the adhesive carefully applied in register with the other layers.
- the upper release layer (with an aperture therein) can then be removed and a replacement release layer applied that covers the observation window.
- the releasable liner 307 has been removed and device 300 is placed within a swab receptacle 400.
- the swab receptacle 400 comprises a transparent tube sized to receive and retain a swab.
- the device 300 is adhered to an inner surface 401 of a sidewall of the receptacle 400 by the outer adhesive layer 306. As the sidewall is transparent, the detection layer 302 is therefore visible to an observer 500 through an outer surface 402 of the sidewall and the observation window 304.
- the swab is of the type standard in medical professions and comprises an elongate handle 403 connected to an ellipsoidal tip 404.
- the analyte is picked up by the tip 404, and the tip 404 is then placed into the receptacle 400.
- the device 300 is positioned such that the tip 404 contacts the first surface 301a of the transfer layer 301.
- the analyte is received by the transfer layer 301 of the device 300.
- the analyte is then transferred by the transfer layer 301 to the detection layer 302 and subsequent detection of one or more biomarkers in the analyte may be visualised by the observer 500, in response to a colour-change.
- Suitable medical devices include: a swab transport tube; swab device; a wound dressing; a chronic wound dressing; a surgical/acute wound dressing; a tube, for example a catheter, or negative pressure wound therapy (NWPT) tubing; a NWPT reservoir or other wound drainage device; a debridement device (physical or ultrasonic); a cannula or infusion device (e.g. insulin infusion device); and a monitor, such as a glucose monitor.
- NWPT negative pressure wound therapy
- the first embodiment of Figure 1 could be in incorporated similarly into a medical device.
- an alternative embodiment such as that of the second embodiment of figures 2 and 3 could be used, with the underside (as illustrated) of the transfer layer 201 suitably attached that the analyte will reach it, for example incorporated into a wound dressing with the underside of the transfer layer 201 facing the wound.
- a fourth embodiment of a detection device 600 like numerals are used to show like features.
- the detection layer of this fourth embodiment comprises three laterally spaced detection zones, each formed from a detection segment 602a-c.
- the device 600 comprises three independent observation windows 604a-c, each in register with, and corresponding to, a respective detection segment 602a-c.
- the device 600 is therefore a multi -detection device 600.
- Each of the transfer layer 601, adhesive layer 603, label 605, and outer adhesive layer 606 of the multi -detection device 600 are shared between the three detection zones respectively.
- the adhesive layer 603 bonds to the transfer layer 601 in the spaces between the corresponding adjacent detection layer segments 602a-c.
- the adhesive layer 603 and transfer layer 601 are bonded together on two opposite sides of each segment 602a-c and thus, the segments forming the detection layer are retained in position in the multi -detection device 600.
- the segments may be arranged differently, for example at points on the circumference of a circle, with gaps between adjacent segments.
- the transfer layer 601 receives the analyte and distributes this to the three detection layer segments 602a-c. As the transfer layer 601 is continuous between the segments, the analyte is thereby effectively distributed between the segments.
- each segment detects biomarkers simultaneously and also independently of the others.
- this provides opportunity for each detection zone to be configured to conduct a different detection or test.
- each detection zone may detect a different set of one or more biomarkers or may be a control zone, in which the segment detects the presence of the analyte and therefore whether detection of biomarkers is possible in the other detection zones.
- the label 605 is printed with two markings 611a-c, 612a-c either side of each detection segment 602a-c to identify each detection zone as discussed in relation to the labelled detection device 200 above.
- a first detection zone is labelled “Tl”
- a second detection zone is labelled “T2”
- a third detection zone is labelled “T3” by markings 612a-c on one side
- a marking 61 la on the other side of the first detection zone is labelled “C” to signify that it is a control zone configured to detect the presence of the analyte.
- the first detection zone is configured to detect the pH of the analyte, as such it changes in colour not only in response to the presence of the analyte but also the pH of the analyte.
- the first detection zone has two functions: 1) it is a control zone, and accordingly any colour change in the first detection segment 602a indicates the analyte has reached the detection layer 602; and 2) it detects the presence of an infection in the analyte, and accordingly the first detection segment 602a turns dark blue if the pH detected indicates the analyte comprises an infection.
- the second detection zone labelled “T2” is configured to detect the biomarker neutrophil elastase
- the third detection zone labelled “T3” is configured to detect the biomarker myeloperoxidase in conjunction with glucose released by the transfer layer 601.
- the first step is cutting glucose filter paper (or another suitable material as described herein) which will form the transfer layer 601 to a suitable size, in this embodiment it is a rectangular size to account for the three detection zones, for example 3 cm x 1 cm.
- each one of the three detection strips corresponding to each detection layer segment 602a-c is cut to a suitable size to form the segment, for example a 5 mm wide strip can be cut into a 5 mm x 10 mm segment.
- each segment will detect a different biomarker.
- the segment 602a that will form the first detection zone may be impregnated with a pH responsive composition which changes colour according to pH; the segment 602b that will form the second detection zone may be impregnated with a chromogenic composition that changes colour on detection of myeloperoxidase; and the segment 602c that will form the third detection zone may be impregnated with a chromogenic composition that changes colour on detection of neutrophil elastase.
- Each segment is then aligned with a 5 mm gap 608 between adjacent segments, and the 10 mm long side of each segment spanning the 1 cm side of the transfer layer 601 to form the detection layer 602.
- the label 605 can be cut from a larger laminate including the adhesive and a release liner. It is cut to match the size of the transfer layer 601, with three apertures, each formed in a position corresponding to the centre of each segment 602a-c. Each aperture is smaller than the width of a segment, e.g. a 4 mm x 4 mm square.
- the release layer is removed and the label 605 adhered by the adhesive layer 603 to the upper surfaces of the detection layer segments 602a-c, and the transfer layer 601 around the periphery of each segment 602a-c. This clamps one to the other whilst leaving the central region of each segment 602a-c free from adhesive and label 605 to form the observation windows 604a-c.
- embodiments of the present invention provide for layered detection devices where the transfer and detection layers are in direct contact. This minimises any interference in the detection process caused by intermediate layers, as the analyte does not pass through any intermediate layers. Furthermore, the device comprises an observation window that facilitates unobstructed observation of any changes in the detection layer of the device caused by markers in the analyte such as biomarkers.
- the device has a simple construction, can be placed in a wide range of medical devices and can be scaled to perform detection of different sets of markers in the analyte simultaneously.
- the transfer layer was exposed to a simulated biological sample, in this case a simulated wound fluid comprising 142 mmol sodium ions and 2.5 mmol calcium ions as chloride salts via a saturated flocked swab.
- the mean fluid absorption of the detection devices was measured as 15.4 mg/cm 2 with a standard deviation of 1.8 mg/cm 2 .
- all devices met the requirement for the detection layer to detect one or more biomarkers in the analyte of 8.4 mg/cm 2 fluid absorption. This shows that the sensor devices absorb sufficient fluid to trigger a reaction in the detection strips.
- Forty -two further detection devices as described above in the fourth embodiment were constructed comprising a T2 detection zone configured to detect elastase and a T3 detection zone configured to detect myeloperoxidase.
- Example 2 For the second half of the devices of Example 2 a myeloperoxidase solution was applied rather than elastase and the resultant colour change of the T3 detection zone measured colorimetrically using a spectrophotometer. The mean percentage uptake by the devices was 66.6% with a standard deviation of 6.8% and all samples exceeded the lower limit required to trigger a valid test of 30%. This shows that the detector constructs are capable of absorbing sufficient myeloperoxidase enzyme to trigger a detection.
- the detection device comprises three detection zones labelled “Tl”, “T2” and “T3” to detect a high pH, elastase and myeloperoxidase respectively.
- the pH detection zone (Tl) is also labelled “C” on a side distal from the “Tl” label as it is also configured to function as a control zone.
- the pH detection zone is initially yellow and is configured to indicate the presence of the biological sample by turning green, furthermore, it is configured to indicate the presence of the biological sample at high pH by turning blue.
- the elastase detection zone, labelled “T2”, is initially pale orange and is configured to turn dark orange/brown if the biological sample comprises the enzyme elastase.
- the myeloperoxidase detection zone, labelled “T3” is initially yellow and is configured to turn brown if the biological sample comprises the enzyme myeloperoxidase.
- the transfer layer of the first test device of Example 3 was exposed to a biological sample of bovine serum albumin (BSA) solution at a low pH. After 5 minutes, the Tl/C zone changed colour to green as the solution was present in the detection layer but not at a high pH. In addition, the T2 and T3 zones did not change colour. This shows that the device is able to detect the presence of a biological sample that does not contain one or more biomarkers.
- BSA bovine serum albumin
- the transfer layer of the second test device of Example 3 was exposed to a low pH solution of myeloperoxidase. After 5 minutes, the Tl/C zone changed colour to green as the solution was present in the detection layer but not at a high pH and the T3 zone changed to a dark brown colour due to the myeloperoxidase in the solution In addition, the T2 zone did not change colour. This shows that the device can detect the presence of a biological sample that does not contain one or more biomarkers in one detection zone and that a different detection zone can detect a different biomarker (or biomarkers) in the biological sample simultaneously.
- Two detection devices as described in relation to Example 3 were constructed however they additionally comprised an outer adhesive layer on the outside of the label and with observation windows corresponding to the three detection zones.
- the detection devices were then mounted on the inside of highly polished plastic tubes via the outer adhesive layer. The resultant changes in the detection zones were then visualised through the plastic tubes.
- the transfer layer of the first test device of Example 4 was exposed to a high pH solution that did not comprise detectable levels of elastase or myeloperoxidase. After 5 minutes, the Tl/C detection zone changed colour to blue due to the presence of the biological sample at high pH. The T2 and T3 detection zones did not change colour. This shows that the Tl/C detection zone of the device is able to detect the presence of a biological sample and also the presence of one or more biomarkers in the biological sample (e.g. an elevated pH).
- the transfer layer of the second test device of Example 4 was exposed to a high pH solution comprising elastase and myeloperoxidase.
- the Tl/C zone changed colour to blue due to the presence of the biological sample at high pH.
- both the T2 and T3 zones had transitioned to a dark brown colour due to the presence of elastase and myeloperoxidase in the biological sample. This shows that each detection zone can simultaneously detect different biomarkers in the biological sample.
- Example 4 demonstrate that the detection layer/detection zones can be visualised through a plastic tube and that the detection device can be easily incorporated into a medical device.
- Example 5
- test device A differed from Test device B and the first embodiment in that the filter paper transfer layer was substituted for a transfer layer comprising a Pall (RTM) Vivid asymmetric polysulfone membrane of grade GF.
- RTM Pall
- Whole blood of concentrations up to 10% was then applied to the transfer layer of both devices. Discolouration of the sensor was prevented by filtration of the blood by the transfer layer of test device A whereas visible discolouration was observed at whole blood concentrations of 1% in test device B. This shows that a simple modification to the device can allow for colorimetric changes to be detected even in the presence of blood pigment. Blood concentrations above 10% were not tested as these are considered heavily blooded samples not suitable for colorimetric testing.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22705455.8A EP4295152A1 (en) | 2021-02-16 | 2022-02-15 | Layered detection device |
US17/671,921 US20220260562A1 (en) | 2021-02-16 | 2022-02-15 | Layered Detection Device |
CN202280014390.0A CN116888472A (en) | 2021-02-16 | 2022-02-15 | Layering detection device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2102163.9A GB202102163D0 (en) | 2021-02-16 | 2021-02-16 | Layered detection device |
GB2102163.9 | 2021-02-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/671,921 Continuation US20220260562A1 (en) | 2021-02-16 | 2022-02-15 | Layered Detection Device |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022175648A1 true WO2022175648A1 (en) | 2022-08-25 |
Family
ID=75338987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2022/050398 WO2022175648A1 (en) | 2021-02-16 | 2022-02-15 | Layered detection device |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202102163D0 (en) |
WO (1) | WO2022175648A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5110724A (en) * | 1990-04-02 | 1992-05-05 | Cholestech Corporation | Multi-analyte assay device |
US5968836A (en) * | 1992-05-12 | 1999-10-19 | Lifescan, Inc. | Fluid conducting test strip with transport medium |
US6506575B1 (en) * | 1999-09-24 | 2003-01-14 | Roche Diagnostics Gmbh | Analytical element and method for the determination of an analyte in a liquid |
US6524864B2 (en) * | 2000-12-28 | 2003-02-25 | Aurora L. Fernandez Decastro | Test strip for simultaneous detection of a plurality of analytes |
US8388907B2 (en) * | 2007-09-11 | 2013-03-05 | University Of Florida Research Foundation, Inc. | Devices and methods for the collection and detection of substances |
WO2017173069A1 (en) | 2016-03-30 | 2017-10-05 | Convatec Technologies Inc. | Detecting microbial infections in wounds |
-
2021
- 2021-02-16 GB GBGB2102163.9A patent/GB202102163D0/en not_active Ceased
-
2022
- 2022-02-15 WO PCT/GB2022/050398 patent/WO2022175648A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5110724A (en) * | 1990-04-02 | 1992-05-05 | Cholestech Corporation | Multi-analyte assay device |
US5968836A (en) * | 1992-05-12 | 1999-10-19 | Lifescan, Inc. | Fluid conducting test strip with transport medium |
US6506575B1 (en) * | 1999-09-24 | 2003-01-14 | Roche Diagnostics Gmbh | Analytical element and method for the determination of an analyte in a liquid |
US6524864B2 (en) * | 2000-12-28 | 2003-02-25 | Aurora L. Fernandez Decastro | Test strip for simultaneous detection of a plurality of analytes |
US8388907B2 (en) * | 2007-09-11 | 2013-03-05 | University Of Florida Research Foundation, Inc. | Devices and methods for the collection and detection of substances |
WO2017173069A1 (en) | 2016-03-30 | 2017-10-05 | Convatec Technologies Inc. | Detecting microbial infections in wounds |
Also Published As
Publication number | Publication date |
---|---|
GB202102163D0 (en) | 2021-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7183146B2 (en) | Detection of microbial infection in wounds | |
US20120264163A1 (en) | Apparatus and method for detecting bacterial growth beneath a wound dressing | |
US10695228B2 (en) | Flexible means for determining the extent of debridement required to remove non-viable tissue | |
AU2009228014B2 (en) | Cotton thread as a low-cost multi-assay diagnostic platform | |
US20070148716A1 (en) | Device for monitoring a patient for a urinary tract infection | |
WO2015192140A1 (en) | Catheter insertion device with blood analyzer | |
US20140296667A9 (en) | Sampling and testing device for the human or animal body | |
WO2008132620A3 (en) | Lateral flow device for attachment to an absorbent article | |
CN109561993B (en) | Determination of wound condition | |
US20220260562A1 (en) | Layered Detection Device | |
WO2022175648A1 (en) | Layered detection device | |
EP3574318B1 (en) | Vertical flow assay device for detecting glucose concentration in a fluid sample | |
US20210190767A1 (en) | Point of care devices and methods for detecting infection status of a wound | |
US11506658B2 (en) | System for analysis of body fluids and wound-associated biomolecules | |
JP4669403B2 (en) | Specimen test tool | |
KR20240038352A (en) | Bio diagnosis monitoring apparatus | |
US20200178893A1 (en) | Hydration testing article | |
KR20240044752A (en) | Bio diagnosis monitoring apparatus using photo detector | |
JP2002253603A (en) | Medical adhesive sheet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22705455 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 202280014390.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022705455 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022705455 Country of ref document: EP Effective date: 20230918 |